OFweek Medical News recently, held in Wuhan Ninth Chinese bio-industry conference, industry sources, the state's key R & D program "Precision Medical Research" 2016 Project of the Year publicity end, approved the project team will proceed. This means that the government plans to continue to invest 60 billion of funds to support medical precision landing officially entered the implementation phase, precise medical operations research major projects have been kicked off. The 13th Five-Year Plan for the upcoming bio-industry will deploy a more future-oriented strategic industry on the original basis, and precision medicine is also a key point. Among them, "life science" has exceeded the existing bio-industry technology, and may include new cutting-edge technologies such as genetic editing, which is expected to play a subversive role in industrial transformation.
China attaches great importance to the research and application of precision medical research, and has given support in policy, capital, technology, etc., and China has abundant clinical resources, and there are a large number of samples, which facilitates the research and development of precision medical treatment. In addition, precision medicine will enable cancer treatment to enter a new era, and it is also the development direction of medical technology, representing the future trend of the international pharmaceutical industry. Gene sequencing is the basis of precision medicine, and it is also a relatively mature link in the field of precision medicine. Recently, the Sino-US joint research team has made important technological breakthroughs in the field of gene sequencing. The new algorithm will reduce the error rate of three generations of sequencing to 0.5%, which is conducive to the upgrade of gene sequencing technology to the third generation.
In summary, precision medical care, as one of the frontiers of the pharmaceutical bio-(Ai, net, information) industry, is driven by government policy support to the launch of related projects and continuous breakthroughs in technology. Commercial applications are expected to gradually open up and have broad development space. When specific event-driven (Aiji, net worth, information) and market risk appetite rise, relevant targets are expected to have better investment opportunities.
A-share precision medical sector opportunity to sort out:
1. Anke Bio (28.30 -0.70%, BUY): Precision Medicine + Anticancer Faucet
2, Dean diagnosis (33.08 -1.40%, buy): precision medicine + anti-cancer
3, Kehua Biology: Precision Medicine + Tumor Detection
4, new open source (62.21 -0.51%, buy): precision medicine + anti-cancer
5, Zuoli Pharmaceutical (9.44 +0.32%, buy): high starting point layout precision medical
Ready To Cook,Ready Prepared Food,Ready To Cook Frozen Food,Frozen Prepared Meals
Guangyun Agricultural Biotechnology (Jiangsu) Co., Ltd , https://www.7-mushrooms.com